

Gianmarco Leone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/708566/publications.pdf>

Version: 2024-02-01

17
papers

191
citations

1163117

8
h-index

1125743

13
g-index

17
all docs

17
docs citations

17
times ranked

475
citing authors

#	ARTICLE	IF	CITATIONS
1	Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103189.	4.4	6
2	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	1.9	30
3	Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era. <i>Lung Cancer</i> , 2021, 157, 85-91.	2.0	6
4	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Lung Cancer</i> , 2020, 139, 47-54.	2.0	28
5	SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit. <i>Frontiers in Oncology</i> , 2020, 10, 1722.	2.8	5
6	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102877.	4.4	14
7	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102994.	4.4	13
8	Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer? a literature review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2674-2685.	2.8	2
9	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 332-347.e2.	1.9	9
10	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2019, 37, 219-219.	1.6	3
11	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R1-R9.	3.1	13
12	Hormonal treatment and quality of life of prostate cancer patients: new evidence. <i>Minerva Urology and Nephrology</i> , 2018, 70, 144-151.	2.5	25
13	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. <i>Cancer Treatment Reviews</i> , 2018, 69, 215-223.	7.7	19
14	Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1087-e1090.	1.9	4
15	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 318-324.	1.9	4
16	Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18719-e18719.	1.6	0
17	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	1.9	10